Floatz logo

Carboplatin

HCV

Universita di VeronaSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the HCV cohort.

Asset / SponsorPhaseRating
sb-497115-gr
GlaxoSmithKline
Phase 3B
Nivolumab
Universita di Verona
Phase 2CCC
Ipilimumab
Universita di Verona
Phase 2CCC
CIS-DIAMMINEDICHLOROPLATINUM II
Universita di Verona
Phase 2CCC
Albuferon
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 1CC
ALBINTERFERON ALFA-2B
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 1CC

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →